New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33810923.
- Also identified by DOI 10.1016/j.eururo.2021.03.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Adjuvant therapy with antiangiogenic agents in locoregional renal cell carcinoma did not translate into a sufficient benefit and highlight the crucial role of patient selection. Ongoing clinical trials with immune-targeted agents hold great promise for this unmet clinical need.
Medical subject headings
- Angiogenesis Inhibitors
- Carcinoma, Renal Cell
- Chemotherapy, Adjuvant
- Kidney Neoplasms